Brinter Inc

3:00 PM - 3:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104A
Brinter is a BioTech/MedTech startup from the US and Finland. With our patented 3D (bio)printing technology, we develop, license, and sell in-vivo applications to our partners and customers.

Our applications are Cartilaginous Bio-Implants for regenerative medicine, and Personalized Drug Printing, for precision medicine.

Our partners and customers are clinics, hospitals, research & academia, CMOs/CROs, bio, and pharmaceutical companies.

Our application development is in North Carolina at Wake Forest WFIRM. Business HQ in Santa Monica, California. Technology R&D is in Finland. Our 17 people are primarily bio-scientists and engineers.

We have $1M in 3D bioprinter hardware sales (2020-22) from our application customers. Other: ~$3M in grants and $1.5M seed round (04/2021). We are currently raising our Series A round ($7M-$15M).

Our strategic investors and EXIT opportunities are in MedTech and Pharma industry (GE HealthCare, J&J MedTech, Roche etc.).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
Cartilaginous Bio-Implants
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
CEO
Brinter Inc